Cervical Cancer | Topics

Lifileucel Plus Pembrolizumab Yields Positive ORR in Advanced Cancers
November 16, 2021

Patients with melanoma, head and neck squamous cell carcinoma, and cervical cancer who had not previously received immunotherapy and were treated with lifileucel plus pembrolizumab experienced promising overall response rates compared favorably with historical data on pembrolizumab monotherapy.

Treatment of Locally Advanced Cervical Cancer With Kidney Failure and Comorbidities
November 16, 2021

In this edition of Clinical Quandaries Eder A. Arango Bravo, MD, and colleagues present a 63 year old woman who has cervical cancer with kidney failure and additional comorbidities.

Cervical Cancer and Grade 3 Cervical Intraepithelial Neoplasia Incidence Reduced in Young, HPV-Vaccinated Individuals
November 04, 2021

Those immunized between the ages of 12 and 13 in England experienced a significant estimated reduction in cervical cancer and grade 3 cervical intraepithelial neoplasia incidence rates compared with unvaccinated women.

Cemiplimab Receives Priority Review From the FDA In Recurrent of Metastatic Cervical Cancer
October 04, 2021

Patients with recurrent or metastatic cervical cancer treated with cemiplimab experienced an improved overall survival, progression-free survival, and overall response rate, leading to priority review from the FDA.

FDA Grants Accelerated Approval to Tisotumab Vedotin in Recurrent Or Metastatic Cervical Cancer
September 20, 2021

Tisotumab vedotin may now be used to treat patients with recurrent or metastatic cervical cancer after the FDA's decision to grant the agent an accelerated approval.

Balstilimab Plus Zalifrelimab Combo May Advance Survival in Patients With Recurrent/Metastatic Cervical Cancer
September 20, 2021

Results of a single-arm study indicate that patients with previously treated metastatic cervical cancer may derive benefit from treatment with balstilimab plus zalifrelimab.

Tisotumab Vedotin Regimens Have Significant Antitumor Activity Across Settings in Metastatic Cervical Cancer
September 19, 2021

Examination of tisotumab vedotin plus key standard-of-care therapeutics shows promise for the treatment of cervical cancer in the frontline setting and beyond.

Potential New Standard of Care in First-Line Cervical Cancer May Include Pembrolizumab Plus Chemotherapy Combo
September 18, 2021

Patients with cervical cancer receiving pembrolizumab plus chemotherapy with or without bevacizumab in the frontline setting had improvement in overall survival, potentially representing a new standard of care regimen.

WHO Releases New Recommendations to Prevent Cervical Cancer Through Increased Access to Screenings and Treatment
August 18, 2021

The World Health Organization has published new recommendations to aid in the global prevention of cervical cancer through more accessible screenings and treatments.

Pembrolizumab Combo Significantly Improved Survival for Persistent, Recurrent, or Metastatic Cervical Cancer
June 23, 2021

Merck’s press release announced positive data from the KEYNOTE-826 trial investigating pembrolizumab plus chemotherapy with or without bevacizumab for patients with cervical cancer.